Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Immune Design CS (IMDZ)

Immune Design CS (IMDZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Immune Design CS 1616 EASTLAKE AVENUE EAST SUITE 310 SEATTLE WA 98102 USA

P: 206-682-0645 F: 206-682-0648

Description:

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.

Key Statistics

Overview:

Market Capitalization, $K 282,935
Shares Outstanding, K 48,365
Annual Sales, $ 2,200 K
Annual Net Income, $ -54,760 K
Last Quarter Sales, $ 480 K
Last Quarter Net Income, $ -13,600 K
60-Month Beta 3.48
% of Insider Shareholders 18.10%
% of Institutional Shareholders 61.72%
Float, K 39,611
% Float 81.90%

Growth:

1-Year Return 77.27%
3-Year Return -58.09%
5-Year Return 0.00%
5-Year Revenue Growth 37.50%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/01/19
Earnings Per Share ttm -0.86
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 44.23%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

IMDZ Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -2.64
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -49.56
Return-on-Assets (Before Tax) -46.21
Profit Margin % -2,489.09
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 128.84
Price/Cash Flow N/A
Price/Book 3.06
Book Value/Share 1.91
Interest Coverage N/A
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar